NCT02844322

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone combined with rituximab or bortezomib regimens in newly diagnosed Waldenström macroglobulinemia patients.

Detailed description

Newly diagnosed WM patients will be randomly assigned to BCD or RCD group for introduction chemotherapy. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will be crossed to control group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patients will quit this study.

Conditions

• Waldenström Macroglobulinemia

Interventions

Type	Name	Description
DRUG	Bortezomib	compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
DRUG	Rituximab	compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia

Timeline

• Start date: 2016-05-01
• Primary completion: 2022-05-01
• Completion: 2023-05-01
• First posted: 2016-07-26
• Last updated: 2026-02-11

Locations

1 site across 1 country: China